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Virus buddingRetroviral Gag proteins encode small peptide motifs known as late domains that promote the release of
virions from infected cells by interacting directly with host cell factors. Three types of retroviral late domains,
with core sequences P(T/S)AP, YPXnL, and PPPY, have been identiﬁed. HIV-1 encodes a primary P(T/S)AP-
type late domain and an apparently secondary late domain sequence of the YPXnL type. The P(T/S)AP and
YPXnL motifs interact with the endosomal sorting factors Tsg101 and Alix, respectively. Although biochemical
and structural studies support a direct binding between HIV-1 p6 and Alix, the physiological role of Alix in
HIV-1 biology remains undeﬁned. To elucidate the function of the p6–Alix interaction in HIV-1 replication,
we introduced a series of mutations in the p6 Alix binding site and evaluated the effects on virus particle
production and virus replication in a range of cell types, including physiologically relevant primary T cells and
macrophages. We also examined the effects of the Alix binding site mutations on virion morphogenesis and
single-cycle virus infectivity. We determined that the p6–Alix interaction plays an important role in HIV-1
replication and observed a particularly severe impact of Alix binding site mutations when they were
combined with mutational inactivation of the Tsg101 binding site.
Published by Elsevier Inc.IntroductionRetroviral particles are generated by the expression of the viral Gag
precursor proteins (Adamson and Freed, 2007; Freed, 1998; Swan-
strom and Wills, 1997). These polyprotein precursors contain func-
tional domains responsible for carrying out all the steps necessary for
virus-like particle (VLP) production. The matrix (MA) domain directs
the association of Gag with the host cell membrane, capsid (CA) and
nucleocapsid (NC) domains mediate Gag–Gag multimerization, and
motifs known as late domains promote the release of virus particles
from the plasma membrane.
Retroviral late domains interact with distinct cellular factors
involved in the endosomal sorting of cargo proteins and the biogenesis
of vesicles that bud into late endosomes to formmultivesicular bodies
(MVBs) (Bieniasz, 2006; Demirov and Freed, 2004; Fujii, Hurley, and
Freed, 2007; Morita and Sundquist, 2004). At the core of this cellular
budding machinery are three multiprotein complexes known as the
endosomal sorting complexes required for transport (ESCRT) I, II, and
III (Hurley and Emr, 2006). Retroviruses, as well as a variety of other
enveloped viruses, have evolved to hijack this cellular budding
machinery to facilitate the pinching off of virus particles from the
infected cell. Retroviruses encode three main classes of late domain.
Pro-Thr/Ser-Ala-Pro (PT/SAP) motifs interact with Tsg101, a compo-Inc.nent of ESCRT-I. Tyr-Pro-Xn-Leu (YPXnL, where X is a variable residue
and n is 1–3) motifs bind the apoptosis-linked gene 2 (ALG-2)-
interacting protein (Alix, formerly known as AIP1), a protein that
harbors binding sites for both ESCRT-I and ESCRT-III. Pro-Pro-Pro-Tyr
(PPPY) motifs interact with members of the Nedd4 family of E3
ubiquitin ligases (Bieniasz, 2006; Demirov and Freed, 2004; Morita
and Sundquist, 2004). Alix is composed of three major structural
domains (Fujii, Hurley, and Freed, 2007; Gottlinger, 2007; Martin-
Serrano and Marsh, 2007): 1) an N-terminal domain that bears
homology to yeast BroI. This domain contains a binding site for the
ESCRT-III component chargedmultivesicular body protein 4 (CHMP4).
2) A central domain that adopts a V-like fold (hence the name V
domain) that binds YPXnL motifs of HIV-1 and EIAV Gag (Zhai et al.,
2008; Fisher et al., 2007; Lee et al., 2007). 3) A proline-rich domain
that binds a number of factors, including the ESCRT-I component
Tsg101 (Fujii et al., 2007; Gottlinger, 2007; Martin-Serrano andMarsh,
2007). Alix functions not only in MVB biogenesis but also in apoptosis,
endocytosis, and cytokinesis pathways (Carlton et al., 2008; Carlton
and Martin-Serrano, 2007; Fujii et al., 2007; Gottlinger, 2007; Morita
et al., 2007; Odorizzi, 2006; Trioulier et al., 2004; Vito et al., 1999).
Many retroviral Gag proteins bear multiple late domains. HIV-1, for
example, encodes two late domain motifs, PT/SAP and YPXnL, in the
p6 region of its Gag precursor protein, Pr55Gag. The PT/SAP motif is
located between p6 residues 7 and 10. The primary Alix binding
sequence is located near the C-terminus of p6, between residues 36
and 44 (36YPLASLRSL44) with p6-Y36, L41, and L44 being particularly
Fig. 1.Mutational analysis of the Alix binding site in HIV-1 p6. (A) Organization of Gag
and the N-terminal region of Pol, including p6⁎ and the N-terminal portion of PR, are
indicated. Amino acid sequence in Gag ofWTand p6mutants is indicated. The Y36A and
L41A mutations also introduced single-amino-acid substitutions in p6⁎, as shown.
Arrowhead indicates the cleavage site between p6⁎ and PR. (B) Sequence of the
peptides used to measure the effects of Alix binding site mutations on binding to the
Alix V domain. The core Alix binding site is shown in bold face text; positions of
mutations are underlined. (C) Measurement of binding between the p6-derived
peptides and the Alix V domain. 50 nM concentrations of the FITC-labeled peptides
were combined with increasing amounts of Alix V domain. Binding was determined by
ﬂuorescence anisotropy.
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et al., 2007; Strack et al., 2003; von Schwedler et al., 2003). Alix has
also been reported to bind the NC domain of HIV-1 p6, perhaps
providing alternative links between Gag and ESCRT-I and ESCRT-III
(Dussupt et al., 2009; Popov et al., 2008). It is well established that the
PT/SAP motif plays a major role in HIV-1 budding. Deletion of p6
severely impairs HIV-1 particle production (Gottlinger et al., 1991), a
defect that maps to the PT/SAP motif (Huang et al., 1995). HIV-1 p6
binds Tsg101 in a PT/SAP-dependent manner (Garrus et al., 2001;
VerPlank et al., 2001), and siRNA-mediated depletion of Tsg101
impairs HIV-1 budding (Garrus et al., 2001). Fusion of Tsg101 to the C-
terminus of HIV-1 p6 rescues the budding defect imposed by PT/SAP
mutation (Martin-Serrano et al., 2001), and overexpression of the N-
terminal, Gag-binding domain of Tsg101 (TSG-5′) blocks HIV-1
budding in a dominant-negative manner (Demirov et al., 2002;
Goila-Gaur et al., 2003).
Whereas the role of Tsg101 in HIV-1 release is well established,
the function of Alix in HIV-1 budding is less clear. Deletions in p6 that
abolish the Alix binding site (Demirov et al., 2002; Gottlinger et al.,
1991; Huang et al., 1995) or mutation of one of the key residues
(Leu41) in this binding site (Huang et al., 1995; Munshi et al., 2007)
do not signiﬁcantly reduce particle production in HeLa or COS cells.
siRNA-mediated depletion of Alix markedly inhibits the release of
equine infectious anemia virus (EIAV) but not HIV-1 (Martin-Serrano
et al., 2003). In contrast, deletion of the Alix binding site does have a
signiﬁcant effect on particle production in the context of a “minimal”
HIV-1 Gag construct from which large regions have been removed
(Strack et al., 2003). Overexpression of the Gag-binding, V domain of
Alix potently inhibits the release of both EIAV (Chen et al., 2005; Lee
et al., 2007; Munshi et al., 2007) and HIV-1 (Lee et al., 2007; Munshi
et al., 2007). The Alix V domain disrupts particle budding by binding
directly to Gag, as mutations in either p6 or the V domain that
abrogate their interaction eliminate the budding defect (Lee et al.,
2007; Munshi et al., 2007). Finally, overexpression of full-length Alix
(Fisher et al., 2007; Usami et al., 2007) or its N-terminal Bro1 domain
(Dussupt et al., 2009) rescues the defect in particle budding imposed
by mutation of the PT/SAP motif. This rescue requires an intact
ESCRT-III binding site in the Bro1 domain (Dussupt et al., 2009;
Fisher et al., 2007; Usami et al., 2007). Although Alix depletion or
Alix binding site mutations do not appear to signiﬁcantly inhibit
HIV-1 budding, they have been reported to reduce the infectivity of
released particles (Fisher et al., 2007; Martin-Serrano and Bieniasz,
2003; Martin-Serrano et al., 2003), perhaps due to defects in virion
morphogenesis.
The studies cited above suggest that under some circumstances
Alix may play a positive role in HIV-1 budding and infectivity;
however, an analysis of the effects of Alix binding site mutations on
HIV-1 release and replication in physiologically relevant cell types has
not been reported. To this end, we introduced a panel of mutations
into the primary Alix binding site in p6 and analyzed the effects on
virus budding in HeLa cells and virus release and replication in T cells
and primary monocyte-derived macrophages (MDMs). The results
demonstrate a cell-type-dependent role for Alix in HIV-1 replication
and also suggest that Tsg101 and Alix function cooperatively in
promoting virus replication.
Results
Mutations between p6 residues 36 and 44 inhibit the Alix-p6 interaction
To deﬁne the relevance of the Alix–p6 interaction in the HIV-1
replication cycle, we introduced a series of mutations into the primary
Alix binding site in p6 in the context of the full-length HIV-1molecular
clone pNL4-3 (Fig. 1A). Biochemical and structural studies implicated
p6 residues Y36, L41, and L44 in Alix binding (Munshi et al., 2007;
Strack et al., 2003; von Schwedler et al., 2003; Zhai et al., 2008).We therefore constructed mutants p6-Y36A, Y36S/L44H, and Y36S/
L44R. For this study, we also used our previously reportedmutants p6-
L41R (Huang et al., 1995) and L41A (Munshi et al., 2007) (Fig. 1A). The
Y36A and L41A mutations also result in single-amino-acid changes in
the overlapping pol open reading frame, in a region referred to as p6⁎
(Fig. 1A).
To determine the effect of the YPXnL mutations on Alix binding, we
used a ﬂuorescence anisotropy-based assay that measures the binding
afﬁnity between the puriﬁed Alix V domain and ﬂuorescently labeled
peptides derived from p6 residues I31 to G46 (Fig. 1B). A ﬁxed amount
of synthetic peptide in solution was incubated with increasing
286 K. Fujii et al. / Virology 391 (2009) 284–292amounts of puriﬁed Alix V. As reported previously (Luttge et al.,
2008), the p6-derived peptide containing the wild-type (WT) YPXnL
motif bound Alix V efﬁciently (Kd ∼15 μM), whereas the mutant
peptides exhibited minimal binding (Fig. 1C). These data indicate that
the YPXnL mutations block the binding between p6 and Alix.
Mutations in the Alix binding site impose variable and cell-type-
dependent effects on Gag processing and virus particle production
Our previous results demonstrated that the L41A and L41R
mutations affect Gag processing but do not inhibit particle release in
HeLa cells (Munshi et al., 2007). To examine the virus release
phenotype of a larger panel of YPXnL mutants in a broader range of
cell types, we performed radioimmunoprecipitation assays not only in
HeLa cells but also in more physiologically relevant cell types, namely,
T cells and MDM. For the HeLa experiments (Fig. 2A), cells were
transfected in parallel with WT or p6-mutant molecular clones and
were metabolically labeled with [35S]Met/Cys. The levels of cell- and
virion-associated HIV-1 proteins were determined by radioimmuno-
precipitation of cell and virion lysates with anti-HIV-1 immunoglo-
bulin (HIV-Ig). Virus release efﬁciency was calculated based on the
levels of virion-associated Gag relative to the total (cell plus virion)
Gag expressed (see Materials and methods). As reported previously
(Munshi et al., 2007), the L41A and L41Rmutations did not reduce the
efﬁciency of virus particle production. However, both L41A and L41R
increased the ratio of p25 (the CA-SP1 Gag processing intermediate)
to mature p24 (CA). This was seen most clearly when the radio-
immunoprecipitates were resolved by polyacrylamide gel electro-
phoresis under conditions that allowed separation of p25 and p24
bands (Fig. 2A, lower gel panel). As reported previously (Huang et al.,
1995), the PTAP− mutation severely (by ∼10-fold) reduced particle
production, as did the PTAP−/L41A double mutant (Fig. 2A). The
Y36S/L44H and Y36S/L44R double mutations did not reduce virus
budding but increased the p25 to p24 ratio (Fig. 2A). Interestingly, the
Y36A mutant exhibited a phenotype distinct from that of the other
Alix binding site mutants; namely, it displayed a marked (∼5-fold)
defect in virus release efﬁciency, coupled with a striking increase in
the ratio of Pr55Gag to p24 (Fig. 2A). This phenotype was observed
consistently in a number of independent experiments (n=7). The
ratio of p25/p24 to Pr55Gag was 1.7±0.59 for the WT and 0.09±0.04
for Y36A. Because the Y36A mutation also introduced a single-amino-
acid change in the overlapping pol-encoded p6⁎ peptide (Fig. 1A), it
seemed possible that the defect in Gag processing and particle release
could be due to dysregulated PR activity. However, we observed that
the Y36Amutation reduced virus particle production by ∼5-fold in the
context of a molecular clone encoding an enzymatically inactive PR
(data not shown). Thus, the Y36A mutation disrupts HIV-1 particle
release independent of PR activity.
We next analyzed the effect of the Alix binding site mutations
on particle release in more physiologically relevant cell types. WT
and mutant virions pseudotyped with vesicular stomatitis virus G
glycoprotein (VSV-G) (see Materials and methods) were used to
infect the Jurkat T-cell line and virus release efﬁciency was measured
by radioimmunoprecipitation. As in HeLa cells, the L41A, L41R, Y36S/
L44R, and Y36H/L44H mutations had no signiﬁcant effect on virus
release, whereas the Y36A mutation severely reduced (by ∼7-fold)
particle production (Fig. 2B). We also consistently observed an
increase in the ratio of Pr55Gag to p24 in cells expressing the Y36AFig. 2. Effect of p6 mutations on HIV-1 particle production in HeLa cells (A), Jurkat T cells (
p6-mutant derivatives. Jurkat cells were infectedwith virus stocks obtained by transfecting H
G (see Materials and methods). Primary MDMs were infected with virus stocks obtained by
pCMVNLGagPolRRE, and pHCMV-G. Transfected or infected cells were metabolically labele
lysates were immunoprecipitated with HIV-Ig and analyzed by SDS-PAGE, followed by p
radiolabeled, virion-associated Gag as a fraction of the total (cell plus virion) radiolabeled G
shown a gel run under conditions that optimize the separation of CA-SP1 (p25) and CA (p24)
gp120, the Gag precursor Pr55Gag (Pr55), the Gag processing intermediates p41Gag (p41) anmutant. The PTAP− mutant showed a less pronounced virus release
impairment in Jurkat (2-fold) than in HeLa cells (10-fold), consistent
with our earlier ﬁndings (Demirov et al., 2002). We also examined the
effect of the Alix binding site mutations on virus release in primary
MDMs (Fig. 2C). Interestingly, not only the L41A, L41R, Y36S/L44R,
and Y36S/L44H mutants but also the Y36A mutant showed levels of
virus release that were reduced by no more than ∼40%. Likewise, the
PTAP− mutant displayed only a modest impairment in particle
production in this primary cell type. However, combining mutations
in the Tsg101 (PTAP−) and Alix (L41A) binding sites led to a severe (5-
fold) defect in particle production (Fig. 2C).
Mutations in the Alix binding site impair HIV-1 replication, particularly
when coupled with disruption of the PTAP motif
To evaluate the effect of Alix binding site mutations on virus
replication kinetics, we transfected two T-cell lines, Jurkat and CEM
(12D7), with full-length pNL4-3 derivatives bearing the Alix binding
site mutations, the PTAP− mutations, or combined PTAP− and L41A
mutations. Virus replicationwas monitored bymeasuring the levels of
reverse transcriptase (RT) activity in the medium over time. As we
demonstrated previously (Demirov et al., 2002), the PTAP− mutant
replicated with some delay relative toWT in Jurkat T cells (Fig. 3A) but
showed no detectable replication in CEM(12D7) (Fig. 3B). In Jurkat
cells, the Alix binding sitemutants displayed signiﬁcant delays relative
to WT, with peak RT levels occurring ∼1–2 weeks later than observed
with the WT. In CEM(12D7), replication of the Alix binding site
mutants peaked 4–6 days later than WT. Interestingly, combining the
PTAP− and L41mutations abolished virus replication in both cell types
(Figs. 3A and B).
To elucidate the function of the YPXnL motif in HIV-1 replication
in primary CD4+ lymphocytes, we prepared VSV-G-pseudotyped
virus stocks and used them to infect human peripheral blood
mononuclear cells (PBMCs) from several different donors (Fig. 3C).
In general, the Alix binding site mutants displayed moderate to
severe defects in virus replication; however, donor-to-donor varia-
bility was observed. For example, in donor 1, all the Alix binding site
mutants replicated with a signiﬁcant delay relative to the WT. In
donor 2, the Alix binding site mutants produced peak RT levels that
were approximately 2–5-fold lower than those detected in WT-
infected cultures. These data demonstrate that an intact Alix binding
site promotes, but is not essential for, HIV-1 replication in primary
human PBMCs. The PTAP− and PTAP−/L41A mutants showed no
detectable replication in these experiments, although in some assays
measurable replication of PTAP− was observed (data not shown),
consistent with our earlier report (Demirov et al., 2002).
Finally, we tested the phenotypes of the Alix binding site mutants
in primary MDM. The YPXnL Alix binding motif overlaps with the
region of p6 that interacts with the viral accessory protein Vpr (Kondo
and Gottlinger, 1996), and Vpr has been shown to be important for
HIV-1 replication in MDM (Balliet et al., 1994; Connor et al., 1995;
Heinzinger et al., 1994). We therefore performed these experiments in
the context of a molecular clone that is both macrophage-tropic and
lacks an intact Vpr gene [pNL(AD8)R−; (Freed et al., 1995)]. In cells
obtained from two independent donors, we observed that several of
the Alix binding site mutants (Y36A, Y36S/L44H, Y36S/L44R, and
L41R) displayed only modest reductions in peak RT values (Fig. 3D). In
contrast, the L41Amutant showed severely defective virus replication.B), and primary MDM (C). HeLa cells were transiently transfected with WT pNL4-3 or
eLa cells withWTormutant pNL4-3molecular clones, pCMVNLGagPolRRE, and pHCMV-
transfecting HeLa cells with pNL(AD8)R−molecular clones encoding WT or mutant p6,
d with [35S]Met/Cys, and virions were pelleted by ultracentrifugation. Cell and virion
hosphorimager analysis. Virus release efﬁciencies were calculated as the amount of
ag protein detected, ±SE. n=7 (A) or 3 (B and C). In the lower portion of panel (A), is
. Positions of the Env glycoprotein precursor gp160, the mature surface Env glycoprotein
d CA-SP1 (p25), and CA (p24) are shown.
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PTAP− mutant was completely blocked, as was that of PTAP−/L41A
(Fig. 3D).
Morphology of Alix binding site mutants
The biochemical analysis presented above indicated that some of
the Alix binding site mutants, Y36A in particular, induced signiﬁcant
defects in Gag processing, especially in HeLa and Tcells. This raised the
possibility that defects in virion morphogenesis might be observed. To
evaluate this question, we performed thin-section transmission
electron microscopy (EM) of HeLa cells transfected with WT or
mutant molecular clones (Fig. 4A). To quantify these data, 200 virions
per sample were examined and classiﬁed into one of several
categories: released mature, released immature, released aberrant,
budding aberrant, and budding (Fig. 4B). For the WT, approximately
70% of particles were classiﬁed as released mature, with small
numbers of budding and immature virions detected. As expected
(Demirov et al., 2002; Huang et al., 1995), PTAP− and PTAP−/L41A
mutants produced very few mature virions and increased numbers,
relative toWT, of immature particles and tethered budding structures.
While Y36S/L44H, Y36S/L44R, L41A, and L41R mutants produced
signiﬁcant numbers of mature virions (∼50% of the total) they also
showed an increase in the number of immature particles. The most
striking phenotype for the Alix binding site mutants was that of Y36A,
which produced only ∼25% mature virions and a large number
(∼30%) of aberrant particles. These data demonstrate rather modest
effects of most Alix binding site mutations on virion morphology, but
more severe effects in the case of the Y36A mutant. Despite the
increased numbers of aberrant particles observed for Y36A, it is
important to note that this mutant displayed a signiﬁcantly higher
percentage of mature particles than did PTAP− and PTAP−/L41A
(Fig. 4B).
Single-cycle infectivity of Alix binding site mutants
Because the analyses presented in Fig. 3 measure virus replication
in multiple rounds of infection, we wished to determine the effect of
the Alix binding site mutations on single-cycle virus infectivity. For
this purpose, we used the CD4+, CCR5+, CXCR4+ HeLa-derived
indicator cell line TZM-bl, which harbors integrated luciferase and
lacZ reporter genes under transcriptional control of the HIV-1 LTR
(Wei et al., 2002).WTandmutant virus stocks were generated in HeLa
cells, normalized for RT activity, and used to infect TZM-bl cells. We
observed that the Alix binding site mutations reduced infectivity by
approximately two-fold (Fig. 5) under a range of input inocula (data
not shown). In contrast, mutation of the PTAP motif very severely
disrupted virus infectivity. These results demonstrate that mutational
inactivation of the Alix binding site modestly inhibits single-round
HIV-1 infectivity.
Discussion
The results of this study clearly demonstrate a role for the Alix
binding site of p6 in HIV-1 replication. Although all of the mutations
reported here severely disrupt p6–Alix binding, the phenotypes of the
individual mutants are not identical. In particular, the Y36A mutation
imposes a Gag processing defect in HeLa and Jurkat cells that is not
evident with the other mutants; this defect is characterized by an
increase in the ratio of Pr55Gag to p25/p24. The Y36A mutation also
impairs particle budding in HeLa cells, as visualized by the accumula-
tion of defective tethered virions at the plasma membrane.
In addition to the substitution in p6, the Y36A mutation also
introduces a Val-to-Gly change in codon 52 of pol, in the p6⁎ domain
upstream of the PR coding region. It is possible that this substitution in
p6⁎ contributes to the defects in Gag processing and particle buddingobserved with the Y36A mutant. However, in primary MDM this
mutation does not impose a Gag processing defect, and indeed, Y36A
replicates in this primary cell type with kinetics similar to those of the
WT. We also observed that the virus release defect imposed by Y36A
was maintained in the context of an inactive PR. This latter result
indicates that the release defect imposed by Y36A is not a result of
dysregulation of PR activity. Finally, a recent study demonstrated that
substitution of residue 52 of p6⁎ had no effect on HIV-1 replication,
even in highly sensitive virus competition assays (Leiherer et al.,
2009). These observations all suggest that it is the Y36A mutation in
p6, not the V52G change in p6⁎, that is the cause of the defects
observed for Y36A. The L41A mutation also introduces a coding
change in pol, in contrast to L41R, which does not. The phenotypes of
these two mutants are similar in terms of virus release efﬁciency,
virion morphology, replication in T-cell lines and primary T cells;
however, the L41A mutant appears to be more impaired in primary
MDMs.
It is noteworthy that the particle tethering phenotype of Y36A
closely resembles that induced by overexpression of the Alix V domain
(Lee et al., 2007; Munshi et al., 2007). Because several of the Alix
binding site mutants produce virus particles efﬁciently in HeLa cells,
these results suggest that the Y36A mutation, and the overexpressed
Alix V domain, act to disrupt particle budding by mechanisms that
entail more than simply blocking the p6–Alix interaction. The defect
induced by Y36A or by Alix V domain overexpression could, for
example, be caused by global changes in p6 folding which could
potentially inﬂuence the upstream interaction with Tsg101. Because
all of the Alix binding site mutants appear to be severely defective for
p6–Alix interaction (Fig. 1C) yet exhibit some striking differences in
terms of replication capacity and virion morphology, it is possible that
some of the mutations (Y36A in particular) may impose defects in
addition to impaired Alix binding. However, despite their altered
morphology, Y36A virions exhibit reductions in infectivity of only ∼2-
fold. This is likely due to the fact that the Y36Amutant still generates a
signiﬁcant fraction of mature virions (∼2–3-fold reduced relative to
WT as opposed to ∼10–20-fold reduced for PTAP−; Fig. 4B).
Mutations in the Alix binding site resulted in signiﬁcant delays in
virus replication in a range of cell types (Fig. 3). Viruses collected at
the delayed RT peaks demonstrated enhanced replication kinetics
upon repassage in fresh Jurkat T cells relative to the original mutants.
Sequencing of the putative revertant isolates revealed several
potential compensatory mutations (Fujii and Freed, unpublished).
Y36A acquired a p6-L41I mutation. Several of the mutants acquired
single-amino-acid substitutions in the gp120 and gp41 Env glycopro-
teins and also truncations in the Vpu open reading frame. Whether
these p6, Env, and Vpu mutations are able to rescue the replication
defects imposed by the Alix binding site changes, and the mechanism
by which they might do so, are currently under investigation.
With the exception of Y36A, the virus release defect in HeLa cells
imposed by Alix binding sitemutations is considerably less severe than
that observed with PT/SAP mutations that disrupt the p6–Tsg101
interaction. As reported earlier for L41A and L41R (Munshi et al., 2007),
the only indication of a budding defect formost of themutants in HeLa
cells is an increase in the levels of the Gag processing intermediates
p25 (CA-SP1) and p41 (MA-CA) (Fig. 2A and data not shown). Because
the processing of CA-SP1 to CA occurs late in the Gag processing
cascade, CA-SP1 accumulation frequently accompanies a budding
block (Demirov et al., 2002; Garrus et al., 2001; Gottlinger et al., 1991).
Although the release defect imposed by PT/SAP mutations is more
severe than that observed for Alix binding site substitutions, the latter
class of mutants displayed signiﬁcant and cell-type-dependent defects
in virus replication. For example, in Jurkat T cells, mutation of Y36, L41,
and L44 had a more severe effect on virus replication kinetics than did
the PTAP−mutation. The situationwas reversed in CEM(12D7) cells in
which, as reported previously (Demirov et al., 2002; Huang et al.,
1995), the PTAP− mutant showed no detectable replication whereas
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cantly from a biological relevance point of view, in primary MDM the
Alix binding site mutations were relatively well tolerated whereasFig. 3. Effect of p6 mutations on virus replication in the Jurkat (A), or CEM(12D7) (B)
T-cell lines, PBMC (C), and primary MDM (D). Jurkat and CEM(12D7) T-cell lines were
transfected with WT or p6-mutant pNL4-3 molecular clones. Cells were split and
culture supernatants collected for RT analysis every 2–3 days. PBMCs were infected
with virus stocks obtained by transfecting HeLa cells with WT or the indicated mutant
pNL4-3 molecular clones, pCMVNLGagPolRRE, and pHCMV-G. MDMs were infected
with virus stocks obtained by transfecting HeLa cells with pNL(AD8)R− molecular
clones encoding WT or mutant p6, pCMVNLGagPolRRE, and pHCMV-G. Culture
supernatants were reserved every 2 days for RT analysis.
Fig. 3 (continued).the PTAP− mutations completely blocked replication. Regardless of
the relative impact on virus replication of mutations in the Tsg101
and Alix binding sites, combining these two sets of mutations (e.g.,
PTAP−/L41A) consistently resulted in a highly defective phenotype,
independent of host cell type. One possible explanation for the dif-
ferences in severity of Alix binding sitemutations is that the target cell
types analyzed here express different levels of Alix and Tsg101. For
example, cell types that express high levels of Alix and low levels of
Tsg101 would be predicted to be more dependent on Alix for the
establishment of a productive spreading infection; conversely, very
high levels of Alix expression could promote Tsg101-independent
release, as has been observed (Fisher et al., 2007; Usami et al., 2007).
However, we observed that the Jurkat T-cell line expresses higher
levels of Tsg101 than does CEM(12D7) and that both T-cell lines
express comparable levels of Alix (Fujii and Freed, unpublished). These
results suggest that differences inTsg101 andAlix expression levels are
not sufﬁcient to explain the cell-type-dependent phenotypes observed
here. Further studies will be required to clarify this issue, and in a
broader sense, to elucidate the basis for the late domain redundancy so
often observed in retroviral Gag proteins. This is not only an interesting
question from the perspective of understanding virus budding but also
is critical in determining whether successful antiviral strategies that
target virus release will need to simultaneously disrupt Gag interac-
tions with multiple late domain partners.
Materials and methods
Cells
HeLa cells were cultured in Dulbecco's-modiﬁed Eagle medium
supplemented with 10% fetal bovine serum (FBS) as described
previously (Freed and Martin, 1994). The Jurkat and CEM(12D7)
T-cell lines were maintained in RPMI-1640 supplemented with 10%
FBS as previously described (Demirov et al., 2002; Freed and Martin,
1994). Human PBMC and primary MDM were prepared and cultured
as reported (Demirov et al., 2002; Freed et al., 1995; Gousset et al.,
2008). TZM-bl cells (Wei et al., 2002) were obtained from J. Kappes
though the NIH AIDS Research and Reference Reagent Program.
Fig. 4. Effect of p6 mutations on virion morphogenesis. (A) HeLa cells were transiently transfected withWT pNL4-3 or derivatives containing the indicated p6mutations. Transfected
cells were ﬁxed 24 h posttransfection and processed for transmission EM. Scale bar indicates 100 nm. (B) Quantiﬁcation of virion morphology. N200 virions/sample were examined
and categorized as budding, budding aberrant, released aberrant, released immature, and released mature.
290 K. Fujii et al. / Virology 391 (2009) 284–292Plasmids, mutagenesis, and DNA cloning
The full-length HIV-1 molecular clones pNL4-3 (Adachi et al.,
1986), the macrophage-tropic derivative pNL(AD8) (Freed et al.,1995), and the Vpr-defective pNL(AD8) [pNL(AD8)R−; (Freed et al.,
1995)) were used for this study. The PTAP−, L41R (Huang et al., 1995)
and L41A (Munshi et al., 2007) mutants have been described
previously. The remaining mutants were constructed by PCR-based
Fig. 5. Effect of Alix binding site mutations on single-cycle infectivity. Virus stocks were
prepared in HeLa cells, normalized for RT activity, and used to infect TZM-bl cells.
Luciferase activity was measured two days postinfection. nN3, ±SD.
291K. Fujii et al. / Virology 391 (2009) 284–292mutagenesis methods as reported (Goila-Gaur et al., 2003). Primer
sequences will be made available upon request. The pNL(AD8)R−
versions of the p6 mutants were constructed by introducing the
PﬂMI–BamHI fragment (pNL4-3 nucleotide 5304–8466) from pNL
(AD8)R− into the pNL4-3 derivatives containing the Alix binding site
mutations. Plasmid DNA was puriﬁed with the plasmid puriﬁcation
maxi prep kit (QIAGEN, Valencia, CA).
Transfections, preparation of virus stocks, and infections
HeLa cell transfections were performed with the Lipofectamine
2000 reagent (Invitrogen, Carlsbad, CA) according to the manufac-
turer's instructions. Jurkat and CEM(12D7) T cells were transfected
with DEAE-dextran as previously reported (Freed et al., 1994). For
preparing VSV-G-pseudotyped virus stocks, HeLa cells were cotrans-
fected with WT or mutant molecular clones, a VSV-G expression
vector [pHCMV-G (Yee et al., 1994)] and the WT HIV-1 GagPol
expression plasmid pCMVNLGagPolRRE (Ono and Freed, 2001).
Transfected-cell supernatants were passed through a 0.45-μm-pore-
size ﬁlter, normalized for RT activity (Freed and Martin, 1994), and
used in infections as indicated. Infections of T-cell lines, PBMC, and
MDM were performed as described (Demirov et al., 2002). Virus
stocks were normalized for RT activity prior to infections. Infectivity
assays in TZM-bl cells were performed as reported (Waheed et al.,
2006).
Radioimmunoprecipitation and Western blot analysis
The quantitative radioimmunoprecipitation virus release assay has
been described in detail previously (Demirov et al., 2002; Waheed
et al., 2009). Brieﬂy, transfected or infected cells were metabolically
labeled with [35S]Met/Cys. After approximately 16 h of metabolic
labeling, virions were pelleted by ultracentrifugation. Cell and virus
lysates were immunoprecipitated with HIV immunoglobulin (HIV-Ig)
obtained from the NIH AIDS Research and Reference Reagent Program
and subjected to sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis (SDS-PAGE), followed by ﬂuorography. Virus release efﬁ-
ciency was calculated as the amount of virion p24 divided by total Gag
(cell Pr55Gag+cell p24+virion p24). For resolution of p25 (CA-SP1)
and p24 (CA) bands, samples were separated by SDS-PAGE on 12% gels
for 4–5 h at 200 V.
EM analysis
Transfected HeLa cells were ﬁxed in 2% glutaraldehyde-100 mM
sodium cacodylate solution. The methods for transmission EM were
described previously (Freed et al., 1994).Fluorescence anisotropy
The methods used for puriﬁcation of the Alix V domain have been
described (Luttge et al., 2008). Custom peptides were synthesized and
amino terminally labeled with ﬂuorescein isothiocyanate (FITC;
EZBiolabs). FITC-conjugated peptides at 50 nM were incubated with
1 to 100 μM concentrations of puriﬁed Alix V domain. Methods for
detection of protein–peptide interactions by ﬂuorescence anisotropy
have been described previously (Liu et al., 2006).
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